Custom RNA Development –
From Idea to Impact.
Aurora Biosynthetics accelerates the development and manufacturing of transformative RNA therapeutics and vaccines through our proprietary, fully integrated platform. We offer comprehensive, streamlined solutions that empower biotechnology innovators worldwide to rapidly bring high-quality therapies to patients.
Who We Are
Aurora Biosynthetics is a state-of-the-art RNA manufacturing partner providing comprehensive, end-to-end solutions for the production of critical drug components, including plasmid DNA, mRNA, and lipid nanoparticles (LNPs). Located in Sydney, Australia, Aurora integrates process and analytical development, GMP manufacturing, and fill/finish services under one roof. This streamlined approach significantly reduces manufacturing risks and accelerates timelines, enabling biotechnology and pharmaceutical companies worldwide to rapidly advance their innovative RNA-based therapies.
Leveraging strategic public-private partnerships and deep industry expertise, Aurora is uniquely positioned to address the growing global demand for reliable, high-quality RNA manufacturing solutions.
What We Do
Aurora Biosynthetics leverages world-class expertise in RNA manufacturing, enhanced by strategic support from RNA Australia and the New South Wales (NSW) Government. This strategic collaboration empowers Aurora’s rapid establishment, scalable growth, and strong entry into the global RNA therapeutics manufacturing market.
Aurora Biosynthetics is uniquely positioned to deliver fully-integrated, end-to-end RNA manufacturing solutions, enabling seamless advancement from therapeutic development to commercialization, including:
Our Services
DNA Production
Production
(LNP) Formulation
This comprehensive suite of services enables Aurora to offer a streamlined, one-stop solution that reduces complexity and accelerates time-to-market for its collaborators and clients.
Partnering for Success
Aurora Biosynthetics is driven by a clear and ambitious mission: to become the most trusted RNA manufacturing partner for leading biotechnology and pharmaceutical companies worldwide. We understand that trust is earned through consistent excellence, collaboration, and shared success—and we are committed to delivering on these promises from the outset.
Supported by a significant AU$200 million investment from the NSW Government to strengthen Australia’s RNA ecosystem, Aurora’s state-of-the-art manufacturing facility is strategically located at Macquarie Park in Sydney. This prime location positions Aurora to foster close collaborations with top academic researchers and tap into a highly skilled workforce, accelerating innovation and leadership in RNA therapeutics globally.
What Our Partners Are Saying
“Building a sovereign RNA ecosystem isn’t just a strategic priority—it’s an opportunity to shape the future of healthcare, biotechnology, and advanced manufacturing. The NSW Government has committed over $200 million to this national endeavour, and Aurora Biosynthetics’ RNA manufacturing facility is at the heart of it. That’s why we’re backing the construction of this critical capability—because with Aurora, we’re building the foundation for Australia to not just participate in the RNA revolution, but to lead it.”
“Many biotechs are taking on the toughest challenges to create innovative and vital in vivo therapeutic solutions to people who need them most. We have clinical trials ongoing and an emerging pipeline of in vivo drugs that have spanned from our groundbreaking drug discovery methods. We are proud to be working with Aurora, who has been a trusted partner since September 2024, and has been instrumental in helping us drive our programs toward patients in need.”